Currus Biologics is developing proprietary BEAT technology to enable CAR-T cell therapies for the treatment of solid tumors, which are typically resistant to existing CAR-T approaches. This technology allows for the genetic engineering of T-cells to produce chimeric antigen receptors that specifically target and eliminate cancer cells in breast, colon, pancreatic, and prostate cancers.
Funding
$7.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors have proven largely resistant to existing CAR-T cell therapies, limiting the effectiveness of this treatment approach for cancers such as breast, colon, pancreatic, and prostate cancers. Traditional CAR-T cell therapies face challenges in penetrating the tumor microenvironment and maintaining efficacy within solid tumors.
Solution
Currus Biologics is developing BEAT technology, a novel approach to enable CAR-T cell therapies for the treatment of solid tumors. BEAT technology genetically engineers T-cells to produce chimeric antigen receptors (CARs) that specifically target and eliminate cancer cells within solid tumors. This technology overcomes many of the challenges presented by traditional CAR-T cell therapies when treating solid tumors, potentially expanding the applicability of CAR-T therapy to a wider range of cancers.
Target Audience
The primary target audience includes cancer patients with solid tumors, as well as oncologists and medical researchers focused on developing and improving CAR-T cell therapies.
Features
- Proprietary BEAT technology platform for engineering CAR-T cells
- CAR-T cells engineered to target specific antigens expressed on solid tumor cells
- Designed to enhance CAR-T cell infiltration into the tumor microenvironment
- Aims to improve CAR-T cell persistence and efficacy within solid tumors